OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees under the Company’s 2023 In...
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Viad Corp (NYSE: VVI), a leading global provider of extraordinary experiences, including attractions, hospitality, exhibition management services, and experiential marketing, today reported results for the 2024 first quarter. Steve Moster, Viad’s President and Chief Executive Officer, commented, “We delivered solid first quarter results that were in line with our expectations. Pursuit's 14% revenue growth during the seasonally slower quarter was driven by strong attractions performance, including an impressive launch of our new FlyOver Chicago attraction....
Kura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEG...
Kura Oncology to Report First Quarter 2024 Financial Results SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML – Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, ha...
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- (NYSE: ), a leading provider of extraordinary experiences, including attractions, hospitality, exhibition management services, and experiential marketing, announced today that President and Chief Executive Officer Steve Moster and Chief Financial Officer Ellen Ingersoll will host a teleconference with investors and analysts to review first quarter 2024 results. They will be joined by Pursuit President David Barry. Our call will be held on Thursday, May 2, 2024, at 5 p.m. (Eastern Time). We will issue a press release outlining our financial results and outl...
Kura Oncology to Participate in Stifel Targeted Oncology Forum SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET / 8:30 a.m. PT on April 17, 2024. A live audio webcast of the fireside chat will be available in the Investor...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 49,500 shares of common stock to four (4) new employees under the Company’s 20...
A director at Opko Health Inc bought 500,000 shares at 0.874USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.